• 1
    Shelley MD, Kynaston H, Court J et al. A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001; 88: 20916
  • 2
    Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; 67: 121623
  • 3
    Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 196470
  • 4
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 905
  • 5
    Lightfoot AJ, Rosevear HM, O'Donnell MA. Recognition and treatment of BCG failure in bladder cancer. ScientificWorldJournal 2011; 11: 60213
  • 6
    Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005; 48: 539
  • 7
    Nieder AM, Simon MA, Kim SS, Manoharan M, Soloway MS. Radical cystectomy after bacillus Calmette-Guerin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology 2006; 67: 73741
  • 8
    Soloway MS, Hepps D, Katkoori D, Ayyathurai R, Manoharan M. Radical cystectomy for BCG failure: has the timing improved in recent years? BJU Int 2011; 108: 1825
  • 9
    O'Donnell MA, Boehle A. Treatment options for BCG failures. World J Urol 2006; 24: 4817
  • 10
    Di Lorenzo G, Perdona S, Damiano R et al. Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010; 116: 1893900
  • 11
    Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161: 11247
  • 12
    Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; 163: 7617
  • 13
    Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; 169: 17068
  • 14
    Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder: international Consensus Panel. Urology 2005; 66: 10825
  • 15
    American Urological Association.Guidelines for the Management of Non-Muscle Invasive Bladder Cancer (Stages Ta, T1, and Tis): 2007 Update. Linthicum, MD: AUA, 2007
  • 16
    Brake M, Loertzer H, Horsch R, Keller H. Long-term results of intravesical bacillus Calmette-Guerin therapy for stage T1 superficial bladder cancer. Urology 2000; 55: 6738
  • 17
    Bui TT, Schellhammer PF. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 1997; 49: 68790
  • 18
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Bladder Cancer Including Upper Tract Tumors and Urothelial Carcinoma of the Prostate. Jenkintown, PA: NCCN, 2011
  • 19
    Bajuk M, Oosterlinck W, Sylvester RJ, Kaasinen E, Bohle A, Palou J. European Association of Urology Guidelines on TaT1 (Non-Muscle Invasive) Bladder Cancer. Update 2011. Arnhem: European Association of Urology, 2011
  • 20
    Boström PJ, Alkhateeb S, van Rhijn BW, Kuk C, Zlotta AR. Optimal timing of radical cystectomy in T1 high-grade bladder cancer. Expert Rev Anticancer Ther 2010; 10: 1891902
  • 21
    Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 11249